145 related articles for article (PubMed ID: 22517653)
1. GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?
Gale EA
Diabetes; 2012 May; 61(5):986-8. PubMed ID: 22517653
[No Abstract] [Full Text] [Related]
2. GLP-1 receptor agonist effects on normal and neoplastic pancreata.
Goggins M
Diabetes; 2012 May; 61(5):989-90. PubMed ID: 22517654
[No Abstract] [Full Text] [Related]
3. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
Gier B; Matveyenko AV; Kirakossian D; Dawson D; Dry SM; Butler PC
Diabetes; 2012 May; 61(5):1250-62. PubMed ID: 22266668
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.
Koehler JA; Baggio LL; Lamont BJ; Ali S; Drucker DJ
Diabetes; 2009 Sep; 58(9):2148-61. PubMed ID: 19509017
[TBL] [Abstract][Full Text] [Related]
5. Incretin hormones and the satiation signal.
Holst JJ
Int J Obes (Lond); 2013 Sep; 37(9):1161-8. PubMed ID: 23295502
[TBL] [Abstract][Full Text] [Related]
6. The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.
Vrang N; Jelsing J; Simonsen L; Jensen AE; Thorup I; Søeborg H; Knudsen LB
Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E253-64. PubMed ID: 22589391
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis.
Koehler JA; Baggio LL; Cao X; Abdulla T; Campbell JE; Secher T; Jelsing J; Larsen B; Drucker DJ
Diabetes; 2015 Mar; 64(3):1046-56. PubMed ID: 25277394
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
9. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
Tatarkiewicz K; Belanger P; Gu G; Parkes D; Roy D
Diabetes Obes Metab; 2013 May; 15(5):417-26. PubMed ID: 23163898
[TBL] [Abstract][Full Text] [Related]
10. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
11. Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
Irwin N; Flatt PR; Patterson S; Green BD
Eur J Pharmacol; 2010 Feb; 628(1-3):268-73. PubMed ID: 19917278
[TBL] [Abstract][Full Text] [Related]
12. Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects.
Hartman I; Rojas E; Rodríguez-Molina D
Am J Ther; 2013; 20(4):384-93. PubMed ID: 23459193
[TBL] [Abstract][Full Text] [Related]
13. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.
Chiu WY; Shih SR; Tseng CH
Exp Diabetes Res; 2012; 2012():924168. PubMed ID: 22693487
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.
Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Diamant M; Pieters-van den Bos IC; van Raalte DH; Cahen DL
Diabetes Obes Metab; 2016 Mar; 18(3):281-8. PubMed ID: 26640129
[TBL] [Abstract][Full Text] [Related]
15. PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.
Nakamura T; Ito T; Uchida M; Hijioka M; Igarashi H; Oono T; Kato M; Nakamura K; Suzuki K; Jensen RT; Takayanagi R
Lab Invest; 2014 Jan; 94(1):63-78. PubMed ID: 24217090
[TBL] [Abstract][Full Text] [Related]
16. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.
Kanoski SE; Rupprecht LE; Fortin SM; De Jonghe BC; Hayes MR
Neuropharmacology; 2012 Apr; 62(5-6):1916-27. PubMed ID: 22227019
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
Gallwitz B
Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.
McKay NJ; Kanoski SE; Hayes MR; Daniels D
Am J Physiol Regul Integr Comp Physiol; 2011 Dec; 301(6):R1755-64. PubMed ID: 21975647
[TBL] [Abstract][Full Text] [Related]
20. Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?
Christensen M; Knop FK
Curr Diab Rep; 2010 Apr; 10(2):124-32. PubMed ID: 20425571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
